Shares of Resmed Inc. (RMD) traded over 7% higher in pre-market on Thursday morning after the company’s third-quarter ...

ResMed Inc.’s RMD adjusted earnings per share (EPS) in the third quarter of fiscal 2025 were $2.37, up 11.3% year over year.

ResMed dominates healthcare devices with innovation, recurring revenues, and market leadership. See why we believe RMD stock ...

ResMed Inc (RMD) reports an 8% revenue increase and plans to boost share buybacks, while navigating global trade challenges ...

Resmed has named Salli Schwartz as chief investor relations officer, where she will lead the company’s global investor relations function and report to Mick Farrell, chairman of the board ...

Resmed shares remained unmoved after hours today on third-quarter results that came in ahead of the consensus forecast.

Resmed reported third quarter 2025 revenues of $1.3 billion, an increase of 8% over the same quarter the prior year.

Chief executive Mick Farrell says he’s confident the medical device company’s exports from Australia and Singapore will not ...

Shares of ResMed Inc. RMD advanced 1.52% to $214.08 Tuesday, on what proved to be an all-around great trading session for the ...

Analysts have provided ResMed with 5 ratings, resulting in a consensus rating of Outperform. The average one-year price ...

Reports Q3 revenue $1.3B, consensus $1.28B. “Our positive fiscal year 2025 performance continued in the third quarter, with strong top-line ...

SAN DIEGO (AP) — SAN DIEGO (AP) — ResMed Inc. (RMD) on Wednesday reported fiscal third-quarter profit of $365 million. On a per-share basis, the San Diego-based company said it had profit of $2.48.